Navigation Links
World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients
Date:7/19/2010

ZURICH, July 19, 2010 /PRNewswire/ -- Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.[1]

Spanning 28 countries across 4 continents and involving more than 3300 physicians, A1chieve(R) is set to be the world's largest observational study in insulin therapy.

Approximately 70 percent of the world's 285 million people with diabetes are living in these 28 emerging countries where there is a rising need and interest to look at differences in physician decisions in the management of diabetes.[2]

"Multinational observational studies like A1chieve(R) provide valuable insights in the way current therapies are applied when it comes to varying cultural, economic and epidemiological circumstances," said Philip Home, Professor of Diabetes Medicine at Newcastle University England and Chair of the A1chieve(R) Global Advisory Board.

In order to mimic the natural secretion of insulin in the body, commercially available insulin preparations are used in different ways (regimens) based on an individual's need and prevailing local practices. However it is important to evaluate these different regimens in a real life setting.

"Once completed A1chieve(R) will provide locally relevant information on the effective use of modern insulins across different regimens. This information could be further useful to inform and improve the local guidelines on the management of type 2 diabetes" added Professor Home.

Jesper H0iland, Senior Vice President, Novo Nordisk Region International Operations A/S said "The A1chieve(R) study is another major initiative demonstrating our commitment as leaders in the field of diabetes care. Our vast experience and unmatched presence in the emerging countries has enabled us to carry out such a unique and large scale research activity of clinical importance."

The results of this multinational study will be available in 2011.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit http://www.novonordisk.com.

    Further information:

    References

    1. Siddharth N. Shah, Leon Litwak, Jihad Haddad, Praful N. Chakkarwar and
    Issam Hajjaji. The A1chieve(R) study: a 60,000-person, global,
    prospective, observational study of basal, meal, and biphasic insulin
    analogs in daily clinical practice. Diabetes Research and Clinical
    Practice 88S (2010).

    2. IDF Diabetes Atlas 4th Edition, International Diabetes Federation,
    2009. http://www.diabetesatlas.org.


'/>"/>
SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Frankfurt To Host Worlds Largest Pharmaceutical Services Events In 2011
3. Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Largest Civil Settlement in Pharmaceutical Case Announced by U.S. Department of Justice
5. CyberKnife Radiosurgery Now Reimbursed Throughout France and Largest Italian Region
6. First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity
7. New York States Largest Integrated Health System Chooses Craneware Revenue Integrity Solutions
8. Russias Largest Breast Cancer Oncology Center Uses New CAD Software for Advanced Breast Cancer Detection
9. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
10. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
11. At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... MouthWatch LLC announced today that its flagship product, ... best intraoral camera on DentalCompare,s list of Top Dental ... #1 product was the CollaPlug Absorbable Collagen Wound Dressing ... "…incredibly popular because it is by far the most economical ... price, it doesn,t sacrifice quality imaging." ...
(Date:1/23/2017)... Jan. 23, 2017  Delcath Systems, Inc. (NASDAQ: ... the treatment of primary and metastatic liver cancers, today ... CRNP, President and Chief Executive Officer of Delcath will ... Capital Markets, Thirteenth Annual Investor Conference at the Boca ... Florida , on Tuesday, January 31, 2017 at ...
(Date:1/23/2017)... SAN DIEGO , Jan. 23, 2017 /PRNewswire/ ... identify patients at high risk for acute kidney ... treatment recommended by globally-recognized care guidelines ... moderate to severe AKI more than 33 percent, ... weekend in the journal Intensive Care Medicine. ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy of ... making new water infrastructure a number one priority. “As we usher in a new ... to become a top priority of our new political change agents.” Kleyne pointed out ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... has earned organic certification under the USDA National Organic Program (NOP) for its ... process, we have established organic production and handling systems to complement our current ...
(Date:1/23/2017)... ... ... a story of love and redemption, hope and uncertainty as a girl makes her way ... at the Mill” is the creation of published author, Lois Kulp, who was born in ... County on Crow Hill. The inn, the mill and "Post Yokel" are within ...
(Date:1/23/2017)... ... ... a time when many people celebrate romance and love by giving cards, candy, flowers or ... present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day special: Spend $100 ... $50 free. , “A lot of people just buy the more predictable gift of ...
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian company ... ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding meetings with ... of its beauty and wellness products. At this trade show, the company had the ...
Breaking Medicine News(10 mins):